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Summary
Aim: To compare different method(s) to detect peripheral neuropathy in leprosy
and to study the validity of the monofilament test (MF) and the voluntary muscle test
(VMT) as standard tests of nerve function.
Design: A multi-centre cohort study of 303 multibacillary (MB) leprosy patients.
Methods: Newly registered MB patients requiring a full course of MDT were
recruited in two leprosy outpatient clinics in North India. Controls were people without
leprosy or neurological conditions, attending the dermatological outpatient departments
of the same clinics. Nerve function was evaluated electrophysiologically using standard
parameters for sensory and motor nerve conduction (NC) testing, warm and cold
detection thresholds (W/CDT), vibration perception thresholds, dynamometry, MF and
VMT. The latter two defined the outcomes of sensory and motor impairment.
Results: 115 patients had nerve damage or a reaction of recent onset at diagnosis.
Sensory and motor amplitudes and WDTs were the most frequently abnormal. Among
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the nerves tested, the sural and posterior tibial were the most frequently impaired. In the
ulnar nerve, sensory latencies were abnormal in 25% of subjects; amplitudes in 40%.
Ulnar above-elbow motor conduction velocities were abnormal in 39% and amplitudes
32%. WDTs were much more frequently affected than CDTs in all nerves tested. The
thresholds of all test parameters differed significantly between controls and patients,
while only some differed between patients with and without reaction. Good
concordance was observed between MF results and sensory latencies and velocities
(direct concordance 80% for the ulnar). However, a proportion of nerves with abnormal
MF results tested normal on one or more of the other tests or vice versa. Concordance
between VMT and motor conduction velocities was good for the ulnar nerve, but for the
median and peroneal nerves, the proportion impaired by VMT out of those with
abnormal motor conduction was very low.
Conclusions: Concordance between monofilaments and other sensory function test
results was good, supporting the validity of the monofilaments as standard screening
test of sensory function. Concordance between VMT results and motor nerve
conduction was good for the ulnar nerve, but very few median and peroneal nerves with
abnormal conduction had an abnormal VMT. A more sensitive manual motor test may
be needed for these nerves. Of the nerve assessment tests conducted, NC amplitudes
and warm sensation were the most frequently affected. Therefore, nerve conduction
studies and WDT measurements appear to be most promising tests for early detection
of leprous neuropathy. The pattern of concordance between tactile and thermal sensory
impairment failed to support the hypothesis that small fibre neuropathy always precedes
large fibre damage. Warm sensation was more frequently affected than cold sensation.
This could indicate that unmyelinated C fibres are more frequently affected than small
myelinated Ad fibres.
Introduction
Leprosy is known for the neuropathy it causes. Different methods have been used to detect
leprosy-related nerve function impairment (NFI).1 – 5 More sophisticated methods for
assessing nerve function such as vibrometry,6 laser Doppler flowmetry7,8 and thermal
threshold testing9 have been shown to detect different modalities of leprous neuropathy.
However, it is not known which of these testing methods would detect the neuropathy
earliest. To determine this, the methods needed to be compared in a carefully planned
prospective study.
Many nerve conduction (NC) studies of subjects with leprosy have been reported,
particularly in the 1960 s and 1970 s. Among the earliest were those of Hackett et al.,10
Magora et al.,11 Verghese et al.,12 Antia et al.,13 McLeod et al.,14 and Singh et al.15 With the
exception of the studies of Magora et al. and Samant et al.,16 all these studies were cross-
sectional in nature. The great majority of the studies were small and often a limited number of
nerves was studied, e.g. only ulnar nerves in the study of Hackett et al., the radial cutaneous
nerve by Antia et al.,17 the ulnar and median nerves by Verghese and colleagues or single-
sided nerves, as in the more recent study of Brown et al.,4 Samant et al. did not find
parameters in NC studies that helped predict reactions.18 However, this study had a small
sample size, so associations may have been present, but not statistically significant.
Generally, investigators concluded that nerve conduction studies were very useful and could
potentially detect pre-clinical neuropathy.
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Quantitative sensory testing has opened up new possibilities for the study of sensory
neuropathy.19,20 The most commonly used methods are thermal testing and testing of
vibration sense. Thermal testing assesses small, unmyelinated C-fibres that mediate warm
sensation and small unmyelinated and myelinated Ad fibres mediating cold sensation.21
Vibration ‘sense’ is mediated by large afferent Aab fibres.22 The sensory receptor most
sensitive to vibration stimuli in the glabrous skin is the Pacinian corpuscle.22 – 24 Dyck et al.
introduced automated electronic testing of thermal and vibration perception thresholds in
1978.20 They used a two-alternative forced-choice algorithm to determine the perception
thresholds. Systems have been refined and are now much easier to use. They have been shown
to be a sensitive measure of peripheral sensory function in toxic neuropathies,25 multiple
sclerosis26 and diabetes.27 – 31 and are widely used in the clinical management of people with
diabetes.21,28,31 – 36 These newer techniques hold promise for the study of neuropathy in
leprosy, since there is evidence that small, particularly unmyelinated fibres may be affected
first.37 – 39 Discrimination of warm and cold has been used extensively as a sensory test in
leprosy. However, testing with warm and cold test tubes was cumbersome and the results only
qualitative.4,40 – 45 Electronic thermal testing has been reported, but the study was cross-
sectional and detailed results were not presented.9 Vibrometry has been shown to be useful in
several studies on leprosy, but not necessarily more so than testing with monofilaments.
Hammond and Klenerman reported several studies conducted in India, in which they found
vibration thresholds measured with a biosthesiometer useful for predicting the risk of plantar
ulcers,6 risk of tarsal disintegration,46 and for diagnosing sensory impairment in skin
lesions.47 They showed that vibration sense was affected in 90% of feet at risk of ulceration.
Similar sensitivity was found for abnormal monofilament thresholds. Feenstra et al., also
investigating risk factors for plantar ulceration, concluded that ‘vibrometry was : : : no better
than graded filaments : : : in identifying those at risk’.48
Despite several recent major studies on the epidemiology of neuropathy in leprosy, many
questions remain as yet unanswered. This is partly because much of the current knowledge of
neuropathy in leprosy reactions has come from cross-sectional studies. Little is known about
the longitudinal changes in neurological parameters over time. We do not know which test of
nerve function, is the most sensitive to detect early nerve function impairment and which is
the most dynamic in reflecting the ongoing neuropathogenic processes relating to outcome
events and/or therapy. Nor do we know how well tests of touch sensation, such as the
monofilaments and the ballpoint test, reflect the underlying neuropathy. A recent randomized
trial failed to show a benefit from detecting sensory impairment with monofilaments before
the ballpoint test became abnormal.49 However, does monofilament testing reflect well the
changes in nerve function during steroid treatment? Can treatment outcome be predicted on
the basis of a particular test or combination of tests? Answers to these and other questions
may point to better methods to prevent and treat neuropathy in leprosy.
We have investigated the detection and pathogenesis of neuropathy in leprosy in a large
prospective study. The current report describes the results of neurological examination of the
patients in this cohort at registration, specifically looking at 1) the sensitivity of the different
tests to detect peripheral neuropathy in leprosy and 2) the validity of the monofilament test
(MF) and the voluntary muscle test (VMT) as standard tests of nerve function. Results of the
prospective part of the study will be reported elsewhere.
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Materials and methods
Details of the methods have been given in a parallel publication; only a brief summary will be
given here.50
DESIGN
This was a cohort study of newly-registered MB patients. The patients were then followed up
monthly for 1 year and every 2nd month during the 2nd year.
STUDY POPULATION
The study population included newly registered multibacillary leprosy patients requiring a
full course of MDT.
STUDY SUBJECTS
All newly diagnosed patients who were being registered for MDT and who were smear positive
and/or had six or more skin lesions and/or had two or more nerve trunks involved were eligible
for inclusion. Patients who had a reaction or sensory or motor impairment at diagnosis were not
excluded from the study, but were given steroid treatment (or other anti-inflammatory
treatment as appropriate). Control subjects were people without leprosy or neurological
conditions, attending the dermatological outpatient departments of the same clinics.
OUTCOME EVENTS
The following are counted as outcome events: neuritis, silent neuropathy (SN), type 1 or
reversal reaction (T1R), erythema nodosum leprosum (ENL or T2R), sensory impairment
(SI), motor impairment (MI). The definitions are given in the Appendix.
OUTCOME MEASURES
. Association between nerve function test results and outcome events.
. Median or mean values of test parameters, as appropriate.
. Percentage of patients testing positive for a given measure or marker.
. Odds ratio of a given measure adjusted for the effect of other measures that have a
significant influence on the outcome.
. Early detection of sensory or motor impairment.
The sensitivity and specificity of each test compared with clinically significant NFI
diagnosed with MF or VMT.
GENERAL EXAMINATION AT INTAKE
A standardized history using a checklist was taken from all patients admitted to the study.
A systematic physical and neurological examination was done, giving particular attention
was given to signs and symptoms of type 1 reactions, ENL and peripheral neuropathy.
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TREATMENT REGIMEN
All patients were put on WHO multidrug therapy as described before.50
NERVE FUNCTION ASSESSMENT (NFA)
The study employed a number of tests of nerve function that are not routinely used in the
examination of people affected by leprosy. The outcome events motor and sensory
impairment were defined on the basis of an abnormal VMT or monofilament test result,
because these are standard tests that are widely used. NFA was done using the following
methods.
Motor nerve function
Voluntary muscle testing (VMT) using the 0–5 modified MRC scale.50
Grip dynamometry, key pinch and pulp-to-pulp pinch testing The dynamometer was made
of a sphygmomanometer cuff inserted in a cylindrical cotton cover and inflated to a baseline
pressure of 20 mmHg. Pinch strength was measured in a similar way using a neonatal
sphygmomanometer cuff.5
Motor nerve conduction measurements (MNC) Compound muscle action potentials
(CMAP) parameters were measured on three nerves bilaterally in three nerves following
stimulation at standard distal and proximal sites: ulnar (wrist and above-elbow; abductor
digiti minimi muscle), median (wrist and elbow; abductor pollicis brevis muscle) and
peroneal (ankle and fibular head; extensor digitorum brevis muscle), using Neurocare
2000 EMG machines (BioTech Ltd, Mumbai). The Windows-driven software stores the
CMAP traces in a database for future reference. The measured values for latency,
amplitude and conduction velocity were stored in a separate Access database. Skin
temperatures were measured electronically at both wrists and ankles and the measured
latencies and velocities normalized for a temperature of 338C at the time of analysis
using standard formulae.51
Sensory nerve function
Sensory testing was done using a standard set of coloured Semmes–Weinstein
monofilaments (MF)2 The monofilaments used were 200 mg, 2 g, 4 g, 10 g and 300 g.
Normal reference values were 200 mg for the hand and 2 g for the foot (excluding the heel).52
The test sites and scoring methods are given in a previous publication.50
Sensory nerve conduction measurements (SNC) Antidromic sensory action potential
(SAP) parameters were measured bilaterally on 4 nerves (radial cutaneous, ulnar, median and
sural at a fixed stimulation-recording distance of 14 cm) using the same equipment and
temperature correction procedure as described under MNC.
Vibration perception threshold (VPT) testing VPTs were testing with a Vibrameter II
(Somedic, Sweden). The instrument provides application force-controlled measurements of
the VPTs in microns of skin displacement, using an algorithm of limits (slowly increasing
vibration amplitude, until the person tested indicates that (s)he can feel the vibration. The test
sites were the thenar and hypothenar eminences (soft tissue), for testing the median and ulnar
nerve, respectively, the dorsal first webspace for the radial cutaneous nerve, the plantar pulp
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of the big toe (posterior tibial) and the mid-lateral border of the foot (sural). All tests were
done bilaterally. Details of the testing procedure will be published elsewhere.
Thermal threshold testing Thermal thresholds were evaluated with a Thermal Sensory
Analyzer (TSA II; Medoc, Israel). Warm detection thresholds (WDT) and cold detection
thresholds (CDT) were recorded relative to a baseline thermode temperature of 328C. A
thermode with a surface of 30 £ 40 mm was used. The algorithm used for determining the
threshold was the ‘method of levels’.53 The test sites were the same as for vibrometry,
described above. Details of the testing procedure will be published elsewhere.
ANALYSIS OF RESULTS
The thresholds for impairment of NC, VPT, WDT and CDT are based on the normative
studies done as part of this project and which will be reported in separate publications. From
these, age and sex-group-specific normal thresholds were calculated as the 97·5th percentile
of the log-transformed data. Temperature-corrected latencies and nerve conduction velocities
were used for analysis.51 Each measured nerve function test value in individual patients was
then compared with the appropriate age, sex and centre-specific normal threshold to
determine whether the modality was impaired or not. Cases with an outcome were matched
for leprosy type, bacteriological index, age and sex, although matching on all four variables
was not always possible.
The significance of associations between outcome and predictor variables was
tested using the Chi-squared or Fisher’s exact test. Differences between proportions were
tested with the z-test for differences between proportions. Differences between medians
were tested with the Kruskal-Wallis test for unpaired or the Wilcoxon signed-rank test for
paired comparisons.54 Comparisons between the performance of the new tests and the
reference tests (MF and VMT) are presented as two-by-two tables. Each top left hand cell
corresponds to the co-positivity (‘positive concordance’) and each lower right hand cell to
co-negativity (‘negative concordance’) of the new test and the reference test.55 The term
‘concordance’ is used to describe the direct agreement between the results of two tests in
terms of ‘impaired’ and ‘not impaired’. Analyses were performed using Stata for Windows
software, vs. 7 and 8.
ETHICAL CONSIDERATIONS
Written consent was obtained from individual study subjects before inclusion in the study,
using a standard consent form. No financial incentives were given to participants. Further
details are available in a previous publication.50
Results
A total of 303 subjects were enrolled in the study. The mean age was 32.8 years (range 12–
60). The sex and age distribution of the cohort are presented in Table 1. Altogether 115
subjects had a reaction or NFI event at registration. For the results reported below, the number
of tests was not always the same for each instrument, because of occasional equipment failure
or occasional failure to record the results.
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The frequency of sensory and motor impairment detected by the various tests used is
shown in Table 2. The most frequently affected were SAP and CMAP amplitudes and WDTs.
Interestingly, only in the above-elbow measurements of the ulnar nerve, were CMAP
latencies and velocities more frequently affected than amplitudes. A sensory conduction
block (no measurable latency or amplitude) was observed in a substantial proportion of
nerves (from 10% in the left median nerve to 46% for the left sural nerve). Pooling results for
right and left for nerves where a response was recorded, ulnar sensory latency and amplitude
were abnormal in 60/452 (13%) and 139/452 (31%) of subjects (data not shown). In the case
of motor conduction, total conduction block was much less frequent (0·4–6·6%). Ulnar motor
latency, conduction velocity and above-elbow amplitudes were abnormal in 177/511 (35%),
196/511 (38%) and 157/511 (31%), respectively. A large discrepancy was found between the
frequency of motor impairment detected by VMT and MNC. This was particularly
pronounced in the median and peroneal nerves. Overall, on the sensory tests, the sural and
posterior tibial nerves were the most frequently impaired. WDTs were affected as least twice
as often as CDTs in the ulnar and median nerves. This difference was less pronounced on the
lower limb. If non-conducting nerves were included, SAP amplitudes were significantly more
often abnormal than WDT (e.g. 43% versus 19% for the right ulnar, P , 0·0001), while,
except in the right ulnar nerve, the latter was significantly more often affected than the
monofilament test (Table 2). It is noteworthy that 119/522 ulnar nerves (23%) had
impairment of one or more MNC parameters, while SNC was normal (data not shown). Out of
these 119, a further 22 had an abnormal WDT and/or CDT. When comparing VMT and MF
results, 21/606 ulnar nerves (3·5%) had an abnormal motor function, while sensation was
normal.
Table 3 compares the results of nerve conduction testing, WDT, CDT, VPT and
dynamometry of the ulnar nerve, between controls, patients with and patients without
reaction at the time of registration. For all tests, the difference between controls and patients
was highly statistically significant. Significant differences were observed also between
reaction and non-reaction patients in SAP distal latency and velocity, in CMAP latencies and
amplitudes at the wrist, above-elbow CMAP amplitudes, and in VPTs. Differences in median
WDT and CDT were significant between the controls and non-reaction patients, but the
magnitude of the differences was very small. The mean strength in each of the dynamometry
parameters recorded (grip, key pinch and pulp-to-pulp pinch) differed significantly between
patients with and without a reaction.
Table 1. Characteristics of the subjects in the INFIR Cohort Study (n = 303) at the time of registration
Variable Frequency Percentage
Sex
Men 220 72·6
Women 83 27·4
Age group
12–20 56 18·5
21–30 97 32·0
31–40 71 23·4
41–50 61 20·1
.50 18 6·0
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Table 2. Number and percentage of nerves scoring impaired, compared to age and sex-specific normal thresholds, on the various nerve function tests used in the INFIR Cohort
Study at the time of registration (n = 303, unless stated otherwise)
Ulnar Median Radial cutaneous Sural Peroneal Posterior tibial
Test* Right Left Right Left Right Left Right Left Right Left Right
Left,
n ¼ (302)
MF 44 (14·5)** 34 (11·2) 22 (7·3) 18 (5·9) 20 (6·6) 19 (6·3) 82 (27·1) 91 (30·0) 90 (29·7) 91 (30·0)
VMT 28 (9·2) 33 (10·9) 3 (0·99) 2 (0·66) 2 (0·66) 2 (0·66)
SNC (n = 263) (n = 263) (n = 262) (n = 261) (n = 259)
No conduction 37 (14·1) 37 (14·1) 32 (12·2) 26 (9·9) 51 (19·5) 52 (19·9) 115 (44·4) 119 (46·0)
Latency (ms) 70 (26·6) 64 (24·3) 59 (22·4) 51 (19·4) 91 (34·7) 86 (33·0) 127 (49·0) 127 (49·0)
Amplitude
(mV)
114 (43·4) 99 (37·6) 100 (38·0) 91 (34·6) 158 (60·3) 140 (53·6) 166 (64·1) 172 (66·4)
Velocity (m/s) 69 (26·2) 64 (24·3) 58 (22·1) 51 (19·4) 91 (34·7) 86 (33·0) 127 (49·0) 127 (49·0)
MNC (n = 263) (n = 262) (n = 260) (n = 259)
Wrist Ankle
No conduction 4 (1·5) 5 (1·9) 2 (0·8) 1 (0·4) 11 (4·2) 17 (6·6)
Latency (ms) 42 (16·0) 36 (13·7) 23 (8·8) 20 (7·6) 34 (13·1) 40 (15·4)
Amplitude
(mV)
64 (24·3) 55 (20·9) 64 (24·4) 65 (24·8) 85 (32·7) 93 (35·9)
(n = 256)
Elbow Fibula
No conduction 4 (1·5) 5 (1·9) 1 (0·39) 1 (0·38) 12 (4·7) 13 (5·1)
Latency (ms) 98 (37·4) 88 (34·1) 48 (18·5) 33 (12·6) 44 (17·2) 37 (14·5)
Amplitude
(mV)
91 (34·7) 75 (29·1) 69 (26·6) 70 (26·8) 87 (34·0) 90 (35·3)
Velocity (m/s) 110 (42·0) 95 (36·8) 46 (17·8) 41 (15·7) 58 (22·7) 49 (19·2)
(n = 296) (n = 295) (n = 293) (n = 295)
WDT (n = 297) 57 (19·2) 68 (22·9) 58 (19·5) 80 (26·9) 120 (40·5) 109 (37·1) 151 (51·2) 159 (53·9) 142 (48·5) 153 (51·9)
CDT (n = 297) 25 (8·4) 35 (11·8) 31 (10·5) 38 (12·8) 88 (29·7) 81 (27·7) 123 (41·7) 137 (46·4) 109 (37·2) 106 (36·1)
(n = 301) (n = 299)
VPT 55 (18·2) 48 (15·8) 52 (17·2) 53 (17·6) 66 (21·8) 62 (20·6) 91 (30·0) 92 (30·7) 100 (33·2) 88 (29·4)
*MF ¼ monofilament test, VMT ¼ voluntary muscle test, MNC ¼ sensory nerve conduction, WDT ¼ warm detection threshold, CDT ¼ cold detection threshold,
VPT ¼ vibration perception threshold.
** Number (%).
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Table 3. Results (medians) of nerve conduction testing and quantitative sensory testing of the ulnar nerve, comparing results of controls and patients with and without reaction in
the INFIR Cohort Study at the time of registration
Test*
No.
(nerves) Controls
No.
(nerves) No reaction** Reaction**
Difference, controls vs no
reaction þ
Difference, no reaction vs
reactionþþ
SNC
No conduction 13 31
Latency (ms) 534 2·1 (2·08–2·13)# 135 2·26 (2·21–2·31)** 2·4 (2·3–2·5) 0·0001 0·035
Amplitude (mV) 534 29·5 (28·1–31·8) 135 19·5 (17·0–23·4) 16·8 (14·3–20·7) 0·0001 0·30
Velocity (m/s) 534 57·1 (56·3–57·6) 135 53·0 (52·0–54·3) 49·7 (48·2–52·2) 0·0001 0·041
MNC
Wrist
No conduction 0 5
Latency (ms) 528 2·54 (2·50–2·59) 169 2·76 (2·64–2·83) 2·88 (2·76–3·04) 0·0001 0·001
Amplitude (mV) 528 15·8 (15·3–16·4) 169 15·0 (14·0–15·8) 13·7 (13·1–14·7) 0·0001 0·0023
Elbow
No conduction 0 6
Latency (ms) 514 5·2 (5·1–5·3) 165 5·80 (5·60–5·94) 5·84 (5·70–6·0) 0·0001 0·31
Amplitude (mV) 514 14·6 (14·2–15·0) 165 13·2 (12·0–13·9) 11·5 (10·6–12·8) 0·0001 0·0023
Velocity (m/s) 514 63·0 (62·5–63·7) 165 57·4 (56·2–60·2) 57·5 (55·5–59·2) 0·0001 0·62
WDT 603 33·1 (33·1–33·2) 220 33·8 (33·6–34·0) 33·6 (33·2–33·6) 0·0001 0·15
CDT 604 31·1 (31·1–31·2) 219 31·0 (30·8–31·1) 31·1 (31·0–31·2) 0·0018 0·29
VPT 655 0·71 (0·68–0·75) 230 0·87 (0·78–0·94) 0·98 (0·92–1·10) 0·0001 0·016
Dynamometry ##
Grip (mmHg) 114 240 (220–260) 202 (180–220) ,0·0001
Key pinch 114 150 (142–160) 132 (120–146) 0·0026
Pulp-to-pulp pinch 114 106 (100–110) 92 (90–102) 0·014
*SNC ¼ sensory nerve conduction, MNC ¼ motor nerve conduction, WDT ¼ warm detection threshold, CDT ¼ cold detection threshold, VPT ¼ vibration perception
threshold.
**Matched for leprosy type, age and sex.
þ P-values of significance of the difference between median, based on the Kruskal-Wallis test.
þþP-values of significance of the difference between median, based on the Wilcoxon paired signed rank test.
#Median þ binomial 95% confidence interval.
##Normative study was not done.
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Tables 4 and Table 5 show the concordance between motor and sensory impairment
diagnosed with the VMT and MNC results and monofilament testing and results of SNC and
quantitative sensory testing. Good concordance was observed, particularly between VMT
results and distal motor latency, although positive concordance was highest with
CMAP amplitudes (Table 4). Overall concordance was also good for the median and
peroneal nerves, however, of the nerves testing impaired on MNC, hardly any were impaired
by VMT.
Concordance between monofilament results and SNC varied per type of nerve, but was
generally good (Table 5). Overall concordance was best for SAP latency and velocity, CDTs
and VPTs, while the highest positive concordance was seen between MF results and SAP
amplitudes. Combining impairment of any of the three SNC parameters in one variable did
not improve co-positivity with the MF test, over that of individual SAP parameters, while co-
negativity and overall concordance was substantially lower. These findings indicate that,
most of the time, if touch sensation is affected, one of the SNC parameters will be abnormal
also. Exclusion of non-conducting nerves further improved negative concordance, but
dramatically decreased positive concordance (data not shown).
Positive concordance between monofilaments and thermal thresholds was better for the
radial cutaneous, sural and posterior tibial nerves than for the ulnar and median (Table 5), but
the difference was only statistically significant for the sural nerve. Good positive concordance
indicates that, if touch sensation was impaired, often, thermal sensation was affected also.
This was not true for concordance between MF and VPT, where negative concordance was
much stronger than positive concordance. Negative concordance was generally strong,
showing that if the MF test was normal, most of the time, other tests were normal also.
Although the tests agreed in the large majority of nerves, substantial discordance was
observed in both directions. Nerves testing abnormal on the MF sometimes tested normal on
one or more of the other tests, while up to 61% of nerves with a normal MF result had one or
more abnormalities in sensory nerve conduction testing. Similar results were observed for the
motor assessments.
Discussion
In this study, six nerves commonly affected in leprosy were studied, bilaterally and
prospectively over a period of 2 years from the time of diagnosis in a cohort of 303 patients.
In the current report, we compared sensory and motor nerve conduction results in patients
with reaction against those without reaction and healthy control subjects at baseline only. We
also compared the results of the neurophysiological tests against the monofilament and
voluntary muscle test.
DIFFERENCES BETWEEN HEALTHY CONTROLS AND PATIENTS
Consistent differences in neurological test results were observed between our samples of
healthy control subjects and subjects with leprosy. This highlights the fact that peripheral
neuropathy is a characteristic of leprosy, even though it may not always be detectable with
current routine nerve function tests used in leprosy control programmes. It also shows that
neuropathy is often already well established before the development of reactions.
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Table 4. Concordance between VMT results and motor nerve conduction testing in the INFIR Cohort Study at the time of registration
Left ulnar Right ulnar Left median Right median Left peroneal Right peroneal
Test*
VMT
impaired
VMT not
impaired
VMT
impaired
VMT not
impaired
VMT
impaired
VMT not
impaired
VMT
impaired
VMT not
impaired
VMT
impaired
VMT not
impaired
VMT
impaired
VMT not
impaired
MNC (n = 23) (n = 240) (n = 24) (n = 239) (n = 1) (n = 261) (n = 2) (n = 260) (n = 2) (n = 257) (n = 1) (n = 259)
Wrist/ankle
Latency Impaired 57 (13)** 10 (23) 58 (14)** 12 (28) 0 8·0 (20) 50 (1) 8·0 (22) 100 (2) 15 (38) 100 (1) 13 (33)
Not
impaired
43 (10) 90 (217) 42 (10) 88 (211) 100 (1) 92 (241) 50 (1) 92 (238) 0 85 (219) 0 87 (226)
Amplitude Impaired 78 (18) 15 (37) 88 (21) 18 (43) 100 (1) 25 (64) 50 (1) 24 (63) 100 (2) 35 (91) 100 (1) 32 (84)
Not
impaired
22 (5) 85 (203) 12 (3) 82 (196) 0 75 (197) 50 (1) 76 (197) 0 65 (166) 0 68 (175)
Elbow/fibula (n = 22) (n = 236) (n = 24) (n = 238) (n = 1) (n = 261) (n = 2) (n = 257) (n = 2) (n = 253) (n = 1) (n = 255)
Latency Impaired 68 (15) 31 (73) 67 (16) 34 (82) 0 13 (33) 0 19 (48) 100 (2) 14 (35) 100 (1) 16 (43)
Not
impaired
32 (7) 69 (163) 33 (8) 66 (156) 100 (1) 87 (227) 100 (1) 81 (209) 0 86 (218) 0 84 (212)
Amplitude Impaired 86 (19) 23 (56) 100 (24) 28 (67) 100 (1) 27 (69) 50 (1) 27 (69) 100 (2) 35 (88) 100 (1) 34 (87)
Not
impaired
14 (4) 77 (183) 0 (0) 72 (171) 0 73 (191) 50 (1) 73 (190) 0 65 (165) 0 66 (169)
Velocity Impaired 73 (16) 33 (79) 63 (15) 40 (95) 0 16 (41) 0 18 (46) 100 (2) 19 (47) 100 (1) 22 (57)
Not
impaired
27 (6) 67 (157) 37 (9) 60 (143) 100 (1) 84 (219) 100 (2) 82 (211) 0 81 (206) 0 78 (198)
*MNC ¼ motor nerve conduction.
**Column % (number of nerves).
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Table 5. Concordance between impairment by monofilament test, sensory nerve conduction testing and quantitative sensory testing of five sensory nerves in the INFIR Cohort
Study at the time of registration
Right ulnar Right median Right rad cutaneous Right sural Right posterior tibial
Test* Impaired Not impaired Impaired Not impaired Impaired Not impaired Impaired Not impaired Impaired Not impaired
SNC (n = 40) (n = 223) (n = 20) (n = 243) (n = 19) (n = 243) (n = 68) (n = 191)
Latency Impaired 73 (29)** 18 (41) 70 (14) 19 (45) 84 (16) 31 (75) 93 (63) 34 (64)
Not impaired 27 (11) 82 (182) 30 (6) 81 (198) 16 (3) 69 (168) 7·0 (5) 66 (127)
Amplitude Impaired 78 (31) 37 (83) 80 (16) 35 (84) 100 (19) 57 (139) 94 (64) 53 (102)
Not impaired 22 (9) 63 (140) 20 (4) 65 (159) 0 43 (104) 6·0 (4) 47 (89)
Velocity Impaired 73 (29) 18 (40) 70 (14) 18 (44) 84 (16) 31 (75) 93 (63) 34 (64)
Not impaired 27 (11) 82 (183) 30 (6) 82 (199) 16 (3) 69 (168) 7·0 (5) 66 (127)
SNC Impaired 78 (31) 43 (95) 85 (17) 39 (94) 100 (19) 61 (149) 96 (65) 55 (105)
Combined*** Not impaired 22 (9) 57 (128) 15 (3) 61 (149) 0 39 (94) 4·0 (3) 45 (86)
(n = 43) (n = 254) (n = 21) (n = 276) (n = 19) (n = 277) (n = 80) (n = 215) (n = 83) (n = 210)
WDT Impaired 53 (23) 13 (34) 57 (12) 17 (46) 79 (15) 38 (105) 91 (73) 36 (78) 77 (64) 37 (78)
Not impaired 47 (20) 87 (220) 43 (9) 83 (230) 21 (4) 62 (172) 9·0 (7) 64 (137) 23 (19) 63 (132)
(n = 275)
CDT Impaired 42 (18) 3·0 (7) 38 (8) 8·0 (23) 79 (15) 26 (73) 89 (71) 24 (52) 72 (60) 23 (49)
Not impaired 58 (25) 97 (247) 62 (13) 92 (252) 21 (4) 74 (204) 11 (9) 76 (163) 28 (23) 77 (161)
Thermal Impaired 53 (23) 15 (39) 57 (12) 19 (53) 79 (15) 42 (117) 96 (77) 41 (89) 80 (66) 42 (89)
combined Not impaired 47 (20) 85 (215) 43 (9) 81 (222) 21 (4) 58 (160) 4·0 (3) 59 (126) 20 (17) 58 (121)
(n = 44) (n = 259) (n = 22) (n = 281) (n = 20) (n = 283) (n = 82) (n = 221) (n = 88) (n = 213)
VPT Impaired 50 (22) 13 (33) 68 (15) 13 (37) 55 (11) 19 (55) 59 (48) 19 (43) 70 (62) 18 (38)
Not impaired 50 (22) 87 (226) 32 (7) 87 (244) 45 (9) 81 (228) 41 (34) 81 (178) 30 (28) 82 (175)
*SNC ¼ sensory nerve conduction, SNC comb ¼ combination of abnormal latency or amplitude or velocity, WDT ¼ warm detection threshold, CDT ¼ cold detection
threshold, VPT ¼ vibration perception threshold.
**Column % (number of nerves).
*** Combined ¼ impairment in any of the NC or thermal testing parameters.
W
.
H
.
van
B
rakel
et
al.
288
SENSORY AND MOTOR CONDUCTION
NC measurements in the current study revealed that motor fibres were almost as frequently
affected as sensory fibres. The same was found by was found by Ramadan et al.56 Others
reported more frequent SNC impairment.4,16 Comparing VMT and MF results in the ulnar
nerve, 3·5% had isolated motor impairment. Using nerve conduction tests, 23% of ulnar
nerves had evidence of motor impairment, while sensory conduction was normal. These
findings support earlier clinical reports of isolated motor function impairment in leprosy
patients.57 – 59 The current findings show that this phenomenon is not an artefact of lack of
sensitivity of sensory testing instruments used in the field.
We found a high percentage of concordance between VMT and MNC parameters in the
ulnar nerve, supporting the validity of the ulnar VMT. For the median and peroneal nerves,
negative concordance was high, indicating that most nerves with a normal MNC result also
had a normal VMT. However, of the median and peroneal nerves testing ‘impaired’ by MNC,
hardly any had impairment by VMT. In addition, a substantial proportion of nerves testing
normal on the VMT had abnormal MNC (8–40%). These observations could have two
explanations. First, as observed by Dyck et al., results of nerve conduction tests do not
necessarily correlate well with motor function.60 The impairment observed by MNC thus may
be subclinical and may not translate (yet) into motor weakness. The second possibility is that
the VMT for these nerves (respectively, thumb opposition and foot dorsiflexion) is not
sensitive enough to detect early damage. In the case of the peroneal nerve, however, it should
be noted also that the VMT primarily tests muscle strength in the tibialis anterior muscle,
while CMAP recordings were taken from the extensor digitorum brevis.
Concordance between MF and SNC was good and was highest with SNC latency and
velocity, confirming earlier findings by Breger.61 However, a substantial proportion of nerves
impaired by VMT or monofilaments (Tables 4 and 5) were not impaired by MNC or SNC.
Maybe the VMT/MF detect functionally important impairment not necessarily reflected in
nerve conduction, which is studied over a relatively short segment of the peripheral nerve. It
is known that the severity of abnormality of conduction velocity does not relate well to global
severity of neuropathy.60 In the present study, except for the radial cutaneous and sural
nerves, negative concordance was comparatively high, i.e. if VMT or monofilaments were
negative, NC results were often also normal. The same was reported by Brown et al.4 The
higher positive concordance and relatively lower negative concordance of the radial
cutaneous and sural NC may be due to the fact that for these nerves, only a single site was
tested with monofilaments, while multiple sites were tested for the ulnar, median and
posterior tibial nerves. Fifty-five to 61% of the radial cutaneous and sural nerves that tested
normal on the MF were impaired on SNC, while this was 39–43% for the median and ulnar
nerves. This suggests that testing only one site for a given nerve may be insufficient, leading
to more under-diagnosis of sensory impairment. However, a proportion of the nerves testing
normal on VMT or on multiple monofilaments test sites also had abnormal nerve conduction.
This has also been observed by other investigators4,10,14 and may indicate a pre-clinical stage
of neuropathy, as suggested by Hackett et al. and Brown et al.4,10 Whether this is the case
may become clear from the analysis of the longitudinal data from current study (van Brakel
et al., in preparation).
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QUANTITATIVE SENSORY TESTING: THERMAL TESTING AND VIBROMETRY
The Thermal Sensory Analyzer II used in this study was very easy to operate. The test is
highly relevant in leprosy, because lack of warm sensation frequently causes injury in people
with sensory impairment. The ‘levels’ algorithm provided highly reliable threshold results (to
be reported elsewhere), but sometimes took a long time to complete, particularly in people
with incomplete sensory impairment on the feet. In such situations, the test could take more
than an hour to complete on five nerves bilaterally.
On grounds of histopathological evidence, indicating that small, unmyelinated fibres are
the first to be affected in leprosy,37 – 39 we had postulated that thermal sensation would be
impaired before touch sensation. In the current cross-sectional analysis, this would have
meant that all nerves impaired on the monofilament test would also have impaired thermal
sensation. In addition, a proportion on nerves would have impaired thermal sensation, but
normal touch sensation. The association between temperature sensation and touch sensation
was strong, but did not follow the expected pattern. This may have four explanations. First,
the patchy nature of leprous neuropathy causes different levels of impairment at different
sites and in different people, despite the fact that small fibres are affected before the large
ones. This effect may have been exaggerated by the way the tests were performed. The ulnar-
innervated area on the palm was tested at three different sites with the monofilament test,
while only the hypothenar eminence was tested for thermal sensation. Both are standard
testing practice. If sensory impairment is localized, due to the inhomogeneous nature of the
neuropathy, it is possible that the monofilaments picked up impairment at the 5th metacarpo-
phalangeal joint or little finger tip missed by the thermal test. Support for the latter
explanation may be found in the fact the positive concordance between the two tests was
considerably higher for the radial cutaneous and sural nerves, both of which were
monofilament-tested at only one site. If this explanation were true, it would support the
practice of testing at least two or three sites per nerve, rather than only one. Second, we have
not tested small fibres responsible for autonomic innervation. It is therefore possible that
those patients who had impaired touch, but normal thermal sensation, had autonomic
neuropathy. Perhaps it is not likely that leprosy would affect thermal sensation selectively in
some and autonomic function in others, but this possibility cannot be excluded on the basis of
the current data. Third, small fibres serving thermal sensation may recover more readily than
large fibres. Thus, nerves currently showing impaired touch sensation without thermal
impairment may have had such impairment initially, but this may have recovered, while
tactile impairment has not. Fourth, it is possible that no association exists between the two
modalities and fibre systems with regard to the sequence of being affected; in some patients
touch sensation is impaired first, in others thermal sensation.
Monofilament and vibration tests both assess large afferent fibre function. It was therefore
expected that vibrometry results would correlate closely with the monofilament test.
However, as with thermal testing, not all nerves with impaired touch had impaired vibration
sense. One explanation again would be the discrepancy in the number of test sites between
MF (usually 3–4) and vibrometry (1). Support for this reasoning can be found in the high co-
negative concordance: if the monofilament test was normal, VPTs were also normal in the
great majority of nerves. Vibrometry is therefore not necessarily more sensitive for detecting
sensory neuropathy in leprosy than monofilament testing.
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DYNAMOMETRY
Dynamometry was done with ‘appropriate technology’ grip and pinch meters made of an
adult and neonatal sphygmomanometer cuff, as described by Soares et al.5 These have
been shown to give reliable results (to be published elsewhere). We found significant
differences in grip and pinch strength between those with a reaction event and age and
sex-matched leprosy controls. Because of large between-subject variations observed during
reliability testing, no normative study had been done. Instead we planned to use a subject
as his or her own control during the prospective analysis. Schreuders showed that the ulnar
nerve has a large influence on grip strength.62 This would support the use of grip
dynamometry in leprosy.
In the current analysis, nerve conduction testing and warm detection thresholds showed
the highest prevalence of impairment. This may indicate that these methods are the most
sensitive for detecting neuropathy in leprosy. However, analysis of the prospective cohort
data will need to confirm this. An important finding is the good concordance between
monofilament and voluntary muscle testing on the one hand and the more sophisticated tests
of nerve function on the other. This supplies additional evidence of their validity to assess
sensory and motor neuropathy. We recommend the use of graded monofilaments and
voluntary muscle testing as standard screening tests for nerve function in the clinical
management of people affected by leprosy. Programme managers and leprosy supporting
agencies should investigate ways to improve the supply of cheap, but standardized
monofilaments to hospitals and health workers responsible for diagnosis and monitoring
treatment of nerve damage.
CONCLUSIONS
. Concordance between MF and other sensory function tests results was good, supporting the
validity of the monofilaments as standard screening test of sensory function.
. Concordance between VMT results and MNC was good for the ulnar nerve, but very few
median and peroneal nerves with abnormal conduction had an abnormal VMT. A more
sensitive motor function test may be needed for these nerves.
. Of the nerve assessment tests conducted, NC amplitudes and WDTs were the most
frequently affected. Therefore, NC studies and WDT measurements appear to be most
promising tests for early detection of leprous neuropathy.
. The pattern of concordance between tactile and thermal sensory impairment failed to
support the hypothesis that small fibre neuropathy always precedes large fibre damage.
. Warm sensation was more frequently affected than cold sensation. This could indicate that
unmyelinated C fibres are more frequently affected than small myelinated Ad fibres.
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Appendix: definitions and diagnostic cut-offs
Non-conducting nerve: A nerve for which the measured latency was less than 1·0 ms for
sensory and less than 3·0 ms for motor nerves.
Neuritis: a leprosy patient has neuritis if he/she has any of the following:
. Spontaneous nerve pain, paraesthesia or tenderness
. New sensory or motor impairment of recent onset (defined below)
Mixed signs neuritis: neuritis may be mild or severe (see below), acute (,1 month
duration), sub-acute (2–6 months) or long-standing (.6 months). During the monthly study
follow-ups, only acute neuritis was regarded as an as outcome.
Silent neuropathy (SN): a patient has silent neuropathy when he/she has sensory and/or
motor impairment of recent onset (,6 months duration) in an area innervated by one or
more nerve without signs of a reaction (RR or ENL) or nerve pain and with or without
tenderness.
Type 1 or reversal reaction (T1R): a type 1 reaction is diagnosed when a patient
has erythema and oedema of skin lesions. There may be accompanying neuritis and
oedema of the hands, feet and face. The skin signs are obligatory; the nerve and general signs
optional.
Erythema nodosum leprosum (ENL): a patient has ENL if he/she has crops of tender
subcutaneous skin lesions. There may be accompanying neuritis, iritis, arthritis, orchitis,
dactylitis, lymphadenopathy, oedema and fever. The skin signs are obligatory; the nerve and
general signs optional.
Sensory impairment: a patient is diagnosed as having sensory impairment in any of the
following situations: the monofilament threshold is increased by three or more levels
(filaments) on any site, OR two levels on one site and at least one level on another site, OR
one level on three or more sites for one nerve.
Motor impairment: a patient is diagnosed as having motor impairment if the VMT score
for any muscle is less than four on the 0–5 (modified) MRC scale.
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New additional sensory or motor impairment: where the baseline showed partial or full
longstanding impairment for two or more consecutive assessments, then if the difference in
‘levels’ (between now and the baseline) is 3 or more for monofilaments or 2 or more for
VMT, then the patient has additional recent impairment and should be considered as having
an outcome event.
Paraesthesia: nerves are marked positive for paraesthesia if the patient
reported sensations of tingling, pricking or something equivalent while the nerve was gently
palpated.
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